Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Perseus Proteomics's FCF Margin % or its related term are showing as below:
TSE:4882'
s FCF Margin % Range Over the Past 10 Years
Min: -988.89 Med: -660.14 Max: -43.69
Current: -489.48
During the past 9 years, the highest FCF Margin % of Perseus Proteomics was -43.69%. The lowest was -988.89%. And the median was -660.14%.
TSE:4882's FCF Margin % is ranked worse than 95.74% of 963
companies
in the Drug Manufacturers industry
Industry Median: 2.57
vs TSE:4882: -489.48
Perseus Proteomics FCF Margin % Related Terms
Perseus Proteomics FCF Margin % Historical Data
* Premium members only.
The historical data trend for Perseus Proteomics's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4882 vs LLY, JNJ, ABBV: FCF Margin % Comparison
For the Drug Manufacturers - General subindustry, Perseus Proteomics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Perseus Proteomics FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Perseus Proteomics's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Perseus Proteomics's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Perseus Proteomics (TSE:4882) has a FCF Margin % of -512.40% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Perseus Proteomics and its competitors. According to the industry distribution chart, Perseus Proteomics ranks #922 out of 963 companies in the Drug Manufacturers industry, placing it in the top 95.7%.
Is Perseus Proteomics' FCF Margin % too high?
Perseus Proteomics' current FCF Margin % is -512.40%. Based on the distribution chart, Perseus Proteomics ranks #922 out of 963 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Perseus Proteomics has a GF Score™ of 56/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Perseus Proteomics' FCF Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Perseus Proteomics ranks #922 out of 963 companies for FCF Margin %. This places Perseus Proteomics in the lower half of its industry. The industry median FCF Margin % is 2.57. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.57, based on 963 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Perseus Proteomics and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Perseus Proteomics's current FCF Margin % is -512.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Perseus Proteomics stock overvalued right now?
Based on GuruFocus' analysis, Perseus Proteomics (TSE:4882) is currently considered Significantly Undervalued. The stock's GF Value™ is 円439.67, compared to a current price of 円160.00 — trading 63.6% below its estimated fair value. The current FCF Margin % is -512.40%. Perseus Proteomics' overall GF Score™ is 56/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Perseus Proteomics (TSE:4882), the current FCF Margin % is -512.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Perseus Proteomics (TSE:4882) Overvalued in 2026?
Based on GuruFocus' analysis, Perseus Proteomics stock appears to be undervalued.
The current stock price of 円160.00 is trading 63.6% below its estimated GF Value™ of 円439.67.
GuruFocus considers Perseus Proteomics to be Significantly Undervalued.
Key valuation signals for TSE:4882:
FCF Margin %: -512.40%
GF Value™: 円439.67 vs. price of 円160.00 (63.6% below fair value)
No single metric tells the full story. See the TSE:4882 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Perseus Proteomics Inc is engaged in the research and development, manufacture, and sales of pharmaceuticals. It provides antibody-based therapeutics and diagnostic drugs to cure cancer and other diseases. The Company operates in a single segment, the pharmaceutical business.
56GF Score
Get the complete analysis for TSE:4882
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4882 has been successfully added to your 
